BeiGene
BGNE
$153.42
Share price
3.27%
Change (1 day)
-37.83%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
Earnings for BeiGene (BGNE)
Earnings in 2023 (TTM): -$1.21 B
According to BeiGene 's latest financial reports the company's current earnings (TTM) are -$1.21 B. In 2022 the company made an earning of -$1.79 B a decrease over its 2021 earnings that were of -$1.44 B.The earnings displayed on this page is the company's Pretax Income.
Earnings history for BeiGene from 2015 to 2023
Annual earnings
| Year | Earnings | Change |
|---|---|---|
| 2023 (TTM) | -$1.21 B | -32.52% |
| 2022 | -$1.79 B | 24.39% |
| 2021 | -$1.44 B | -13.21% |
| 2020 | -$1.66 B | 72.69% |
| 2019 | -$0.96 B | 36.01% |
| 2018 | -$0.71 B | 616.83% |
| 2017 | -$98.46 M | -15.24% |
| 2016 | -$0.12 B | 107.91% |
| 2015 | -$55.88 M |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -$0.19 B | -84.74% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -$18.95 M | -98.43% | 🇺🇸 USA |